drugset / Trial / NCT02035267

Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat

NCT02035267

Phase 3 Completed 93 enrolled Kythera Biopharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The objectives of this study are to explore the safety and efficacy of subcutaneous injections of Deoxycholic Acid relative to placebo, in the submental area in patients with mild or extreme fullness of the submental fat and ratings of 1 or 4.

Timeline

Start
2014-01
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Deoxycholic Acid Small molecule 2 unknown Subcutaneous

Indications

No indication recorded.